Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Baylor College of Medicine
SWOG Cancer Research Network
Novartis
OHSU Knight Cancer Institute
Medical College of Wisconsin
Dana-Farber Cancer Institute
University of Liverpool
University of Jena
Ascentage Pharma Group Inc.
Australasian Leukaemia and Lymphoma Group
Bristol-Myers Squibb
Rennes University Hospital
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
University of Washington
Gruppo Italiano Malattie EMatologiche dell'Adulto
Institut Bergonié
Novartis
Novartis
Novartis
Mansoura University
National Research Center for Hematology, Russia
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Emory University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Norwegian University of Science and Technology
The University of Hong Kong
National Institutes of Health Clinical Center (CC)
Novartis
Dana-Farber Cancer Institute
Novartis
M.D. Anderson Cancer Center
Tongji Hospital
Bristol-Myers Squibb
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Teva Branded Pharmaceutical Products R&D, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Gruppo Italiano Malattie EMatologiche dell'Adulto
Novartis
National Cancer Institute (NCI)